Seattle biotech Silverback Therapeutics raises $85M, just six months after raising $78.5M
- September 24, 2020
Silverback Therapeutics announced that it received $85 million in Series C funding, following closely on the heels of a $78.5 million funding round in March of this year. The capital will go towards advancing its ImmunoTAC programs, currently being developed to use the body’s immune system to fight cancer cells.